Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 7/20 | 0.48 |
| ▸ | PDE5A | O76074 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183953 | 0.83 | GUSB (0.59) | GUSBPDE5ANPC1RAB9ATNKS | |
| SCHEMBL296062 | 0.78 | GUSB (0.70) | GUSBPDE5ANPC1RAB9ATNKS | |
| SCHEMBL7389024 | 0.77 | AMY1A (0.54) | GUSBPDE5ANPC1RAB9AKDM4E | |
| SCHEMBL295966 | 0.77 | GRM2 (0.42) | ELANE | |
| SCHEMBL7396331 | 0.77 | KDM4E (0.53) | PDE5ANPC1RAB9AKDM4EHPGD | |
| SCHEMBL7978070 | 0.75 | AMY1A (0.47) | GUSBNPC1RAB9AKDM4E | |
| SCHEMBL297069 | 0.74 | GUSB (0.67) | GUSBPDE5ANPC1RAB9ATNKS | |
| SCHEMBL7392370 | 0.73 | AMY1A (0.46) | PDE5ANPC1RAB9AKDM4EELANE | |
| SCHEMBL7393381 | 0.73 | PDE5A (0.50) | GUSBPDE5AKDM4EHPGDELANE | |
| SCHEMBL939999 | 0.72 | CFTR (0.46) | GUSBNPC1RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828150-B1 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-1828150-B1 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMA (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366696-A1 | Process for producing 4-aminoquinazolines | Vertex Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1828150-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | Vertex Pharmaceuticals Incorporated (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-27 | — | — | US | disclosed |
| WO-2006066044-A2 | PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166963-A1 | Processes for producing 4-aminoquinazolines | CACNA1I, CACNA1G, CACNA1B | GUSB 4518/4885PDE5A 384/4885NPC1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.